Not available
Quote | Adicet Bio Inc. (NASDAQ:ACET)
Last: | $1.875 |
---|---|
Change Percent: | 1.43% |
Open: | $2.07 |
Close: | $1.875 |
High: | $2.08 |
Low: | $1.865 |
Volume: | 1,352,764 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
News | Adicet Bio Inc. (NASDAQ:ACET)
2024-04-23 06:49:48 ET DENVER, Colo., Apr 23, 2024 ( 247marketnews.com )- Adicet Bio, Inc. (Nasdaq: ACET ) stated that a new preclinical data highlighting ADI-270 was selected for an oral presentation at the ASGCT 27th Annual Meeting on May 10, 2024 in the Targeted Gene and Cell The...
Preclinical findings showed robust anti-tumor activity of ADI-270 in multiple CD70-positive solid and hematological cancer models ADI-270 demonstrated enhanced functional potency and resilience in tumor microenvironment On track to file an investigational new drug (IND) applicatio...
Message Board Posts | Adicet Bio Inc. (NASDAQ:ACET)
Subject | By | Source | When |
---|---|---|---|
AviseAnalytics: 7 REASONS TO PUT ADICET BIO ON YOUR WATCHLIST! $ACET Adicet Bio (NASDAQ: ACET) i | AviseAnalytics | investorshangout | 01/24/2022 12:25:33 PM |
No sell off...guess I bet wrong | masterofdisaster | investorshub | 12/08/2021 7:41:01 PM |
Phase 1's usually suck wind, I lost $80K | TheFinalCD | investorshub | 12/08/2021 2:58:31 PM |
It was weird....I think the MMs drop this | masterofdisaster | investorshub | 12/08/2021 12:07:16 PM |
whats weird is the rally after the offering | TheFinalCD | investorshub | 12/08/2021 4:10:48 AM |
News, Short Squeeze, Breakout and More Instantly...
2024-04-23 06:49:48 ET DENVER, Colo., Apr 23, 2024 ( 247marketnews.com )- Adicet Bio, Inc. (Nasdaq: ACET ) stated that a new preclinical data highlighting ADI-270 was selected for an oral presentation at the ASGCT 27th Annual Meeting on May 10, 2024 in the Targeted Gene and Cell The...
Preclinical findings showed robust anti-tumor activity of ADI-270 in multiple CD70-positive solid and hematological cancer models ADI-270 demonstrated enhanced functional potency and resilience in tumor microenvironment On track to file an investigational new drug (IND) applicatio...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer will participate in a panel at the Canaccord Genuit...